Actively Recruiting
Risk Evaluation by COronary Imaging and Artificial intelliGence Based fuNctIonal analyZing tEchniques - III
Led by Ruijin Hospital · Updated on 2025-01-27
300
Participants Needed
1
Research Sites
182 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a single-center, prospective cohort study. This study is designed to accurately analyze coronary artery plaque characteristics and local hemodynamic parameters in patients diagnosed with chronic coronary syndrome (CCS) or non-ST-segment elevation acute coronary syndrome (NSTE-ACS), with marginal lesions or obstructive lesions in major coronary arteries by multimodality imaging including noninvasive coronary CT angiography (CCTA) and intracoronary imaging techniques, such as intravascular ultrasound (IVUS), optical coherence tomography (OCT), and near infrared spectroscopy (NIRS). The purpose of this study is to improve the accuracy and depth of plaque analysis by CCTA under the guidance of intracoronary imaging, therefore constructing a new CCTA-based high-risk plaque model.
CONDITIONS
Official Title
Risk Evaluation by COronary Imaging and Artificial intelliGence Based fuNctIonal analyZing tEchniques - III
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 218 years
- Diagnosed with chronic coronary syndrome (CCS) or non-ST-segment elevation acute coronary syndrome (NSTE-ACS)
- Underwent coronary CT angiography (CCTA) showing marginal lesions (diameter stenosis between 40%-69%) or obstructive lesions (diameter stenosis 270% or CT-FFR <0.8) in major coronary arteries
- Received invasive coronary angiography and intracoronary imaging (IVUS, OCT, NIRS) within 1 month after CCTA
You will not qualify if you...
- Unsuitable for coronary CT angiography (e.g., severe renal impairment, uncontrolled thyroid condition, allergy to iodine)
- Percutaneous coronary intervention (PCI) within the past 6 months
- Prior history of myocardial infarction or heart failure
- Prior history of coronary artery bypass graft (CABG)
- Abnormal liver function (ALT level exceeding 3 times the upper limit of normal) or abnormal kidney function (eGFR 230%)
- Familial hypercholesterolemia
- Estimated survival of 1 year or less
- Malignant tumor
- Pregnant, breastfeeding, or planning to become pregnant within one year
- Poor compliance or inability to follow up
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China, 200025
Actively Recruiting
Research Team
X
Xiaoqun Wang, M.D., Ph.D.
CONTACT
S
Shuo Feng, M.D., Ph.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here